KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
PITTSBURGH, May 23, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform.
- PITTSBURGH, May 23, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform.
- KaliVir will work with Roche to leverage KaliVir's proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates.
- Under the terms of the agreement, KaliVir will generate oncolytic vaccinia virus product candidates derived from the company's VETTM platform expressing Roche proprietary therapeutic transgenes.
- KaliVir and Astellas Pharma are developing KaliVir's VET2-L2 oncolytic virus for immuno-oncology through a worldwide licensing agreement.